Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $5.678 million which missed the analyst consensus estimate of $10.733 million by 47.10 percent. This is a 88.07 percent decrease over sales of $47.601 million the same period last year.
Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.